Evidence map›Paper›PMID 23312071›Full record

ArticleACS chemical biology2013

Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor.

Min Shan, Kathryn E Carlson, Alexander Bujotzek, Anja Wellner, Ronald Gust, Marcus Weber, John A Katzenellenbogen, Rainer Haag

Abstract read
In one paragraph

Article in ACS chemical biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Drug conjugates-an emerging approach to treat breast cancer.Pharmacology research & perspectives · 2018
    Review
  3. Article
  4. Targeting the androgen receptor with steroid conjugates.Journal of medicinal chemistry · 2014
    Review
  5. Article
  6. [Medicine from the computer].Zeitschrift fur Rheumatologie · 2013
    Article
  7. [Medicine from the computer].Schmerz (Berlin, Germany) · 2013
    Article
  8. [Medicine from the computer].Der Anaesthesist · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min ShanInstitut für Chemie und Biochemie, Freie Universität Berlin, Takustrasse 3, 14195 Berlin, Germany.
Kathryn E Carlson
Alexander Bujotzek
Anja Wellner
Ronald Gust
Marcus Weber
John A Katzenellenbogen
Rainer Haag

Funding

MOLECULAR PROBES FOR STEROID RECEPTORSR37DK015556 · NIDDK · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI KATZENELLENBOGEN, JOHN A. · 1987 to 2012
$4.4M
Novel Ligands and Mechanisms to Achieve Selective Nuclear Receptor ActivityR01DK015556 · NIDDK · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI KATZENELLENBOGEN, JOHN A. · 1986 to 2016
$1.6M
NIDDK NIH HHS 5R37 DK015556NIDDK NIH HHS R01 DK015556NIDDK NIH HHS R37 DK015556
6 · The paper itself

Abstract

The estrogen receptor (ER) is a hormone-regulated transcription factor that binds, as a dimer, to estrogens and to specific DNA sequences. To explore at a fundamental level the geometric and topological features of bivalent-ligand binding to the ER dimer, dimeric ER crystal structures were used to rationally design nonsteroidal bivalent estrogen ligands. Guided by this structure-based ligand design, we prepared two series of bivalent ligands (agonists and antagonists) tethered by flexible spacers of varying lengths (7-47 Å) and evaluated their ER-binding affinities for the two ER subtypes and their biological activities in cell lines. Bivalent ligands based on the agonist diethylstilbestrol (DES) proved to be poor candidates, but bivalent ligands based on the antagonist hydroxytamoxifen (OHT) were well suited for intensive study. Binding affinities of the OHT-based bivalent ligands were related to spacer length in a distinctive fashion, reaching two maximum values at 14 and 29 Å in both ER subtypes. These results demonstrate that the bivalent concept can operate in determining ER-ligand binding affinity and suggest that two distinct modes operate for the binding of bivalent estrogen ligands to the ER dimers, an intermolecular as well as an intramolecular mode. Our insights, particularly the possibility of intramolecular bivalent binding on a single ER monomer, may provide an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.

Indexed as

Cell LineComputer SimulationEstrogensHumansLigandsModels, MolecularReceptors, EstrogenThermodynamicsEstrogensLigandsReceptors, Estrogen

Identifiers

PMID23312071
PMCPMC3631453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.